Atropine 0.5% eyedrops for the treatment of children with low myopia: A randomized controlled trial.
Medicine (Baltimore)
; 96(27): e7371, 2017 Jul.
Article
em En
| MEDLINE
| ID: mdl-28682887
ABSTRACT
BACKGROUND:
This study aimed to assess the efficacy and safety of atropine 0.5% eyedrops (ATE) for the treatment of children with low myopia (LM).METHODS:
In this study, a total of 126 children with LM were randomly divided into an intervention group (administered 0.5% ATE) and a control group (administered a placebo), with 63 children in each group. The outcome measurements were changes in the spherical equivalent (SE), and axial length (AL), as well as adverse events (AEs).RESULTS:
Compared with placebo, administration of 0.5% ATE led to less progression in LM, as measured by SE, and less increase in AL (Pâ<â.01). In addition, no serious AEs occurred in both the groups.CONCLUSION:
About 0.5% ATE was efficacious and safe for controlling myopia in children with LM.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Atropina
/
Antagonistas Muscarínicos
/
Miopia
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article